Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat for the Treatment of Severe COVID-19
2020-002570-27Phase 2Terminated
- Sponsor
- Università di Padova
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Nafabelltan in coronavirus disease 2019 (COVID-19) and airway morbidity (2 arms), sponsored by Università di Padova. Primary endpoint: Clinical efficacy on 7-category ordinal scale. Started Jun 2021; status: terminated.
02
Drugs
Nafabelltan
03
Conditions
coronavirus disease 2019 (COVID-19)airway morbidity
Beyond the preview
Go deeper on 2020-002570-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002570-27.